VERTEX PHARMACEUTICALS INC / MA Cash and Cash Equivalents, Period Increase (Decrease)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Cash and Cash Equivalents, Period Increase (Decrease) of $481.47 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-15.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-02-15
- VERTEX PHARMACEUTICALS INC / MA cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $280.45M, a 39.59% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $161.84M, a 42.18% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $219.45M, a 13438.00% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$180.27M.
- VERTEX PHARMACEUTICALS INC / MA cash and cash equivalents, period increase (decrease) for fiscal 2017 was $481.47M, a 2.62% increase from fiscal 2016.
- VERTEX PHARMACEUTICALS INC / MA cash and cash equivalents, period increase (decrease) for fiscal 2016 was $469.18M, a 424.17% increase from fiscal 2015.
- VERTEX PHARMACEUTICALS INC / MA cash and cash equivalents, period increase (decrease) for fiscal 2015 was $89.51M.
- VERTEX PHARMACEUTICALS INC / MA cash and cash equivalents, period increase (decrease) for fiscal 2010 was -$203.46M, a 453.58% decline from fiscal 2009.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $280.45M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $442.28M derived: sum of 2 quarters · filed 2018-02-15 | $661.73M derived: sum of 3 quarters · filed 2018-02-15 | $481.47M 10-K · filed 2018-02-15 |
| 2017-09-30 | $161.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | $381.29M derived: sum of 2 quarters · filed 2017-10-30 | $201.02M 10-Q · filed 2017-10-30 | $665.27M derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-06-30 | $219.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $39.19M 10-Q · filed 2017-07-28 | $503.44M derived: sum of 3 quarters · filed 2018-02-15 | $617.26M derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-03-31 | -$180.27M 10-Q · filed 2017-04-28 | $283.99M derived: sum of 2 quarters · filed 2018-02-15 | $397.81M derived: sum of 3 quarters · filed 2018-02-15 | $399.43M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-12-31 | $464.25M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $578.08M derived: sum of 2 quarters · filed 2018-02-15 | $579.70M derived: sum of 3 quarters · filed 2018-02-15 | $469.18M 10-K · filed 2018-02-15 |
| 2016-09-30 | $113.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | $115.45M derived: sum of 2 quarters · filed 2017-10-30 | $4.92M 10-Q · filed 2017-10-30 | -$36.56M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $1.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | -$108.90M 10-Q · filed 2017-07-28 | -$150.38M derived: sum of 3 quarters · filed 2018-02-15 | -$264.68M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | -$110.52M 10-Q · filed 2017-04-28 | -$152.00M derived: sum of 2 quarters · filed 2018-02-15 | -$266.30M derived: sum of 3 quarters · filed 2018-02-15 | -$60.63M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | -$41.48M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | -$155.78M derived: sum of 2 quarters · filed 2018-02-15 | $49.89M derived: sum of 3 quarters · filed 2018-02-15 | $89.51M 10-K · filed 2018-02-15 |
| 2015-09-30 | -$114.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | $91.37M derived: sum of 2 quarters · filed 2016-10-31 | $130.99M 10-Q · filed 2016-10-31 | |
| 2015-06-30 | $205.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | $245.28M 10-Q · filed 2016-08-01 | ||
| 2015-03-31 | $39.62M 10-Q · filed 2016-05-03 | |||
| 2014-09-30 | $149.26M 10-Q · filed 2015-10-30 | |||
| 2011-06-30 | $11.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09 | $215.00M 10-Q · filed 2011-08-09 | -$111.71M derived: sum of 3 quarters · filed 2011-08-09 | $120.59M derived: sum of 4 quarters · filed 2011-08-09 |
| 2011-03-31 | $203.34M 10-Q · filed 2011-05-06 | -$123.36M derived: sum of 2 quarters · filed 2011-05-06 | $108.93M derived: sum of 3 quarters · filed 2011-05-06 | $49.99M derived: sum of 4 quarters · filed 2011-08-09 |
| 2010-12-31 | -$326.70M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-17 | -$94.41M derived: sum of 2 quarters · filed 2011-02-17 | -$153.35M derived: sum of 3 quarters · filed 2011-08-09 | -$203.46M 10-K · filed 2011-02-17 |
| 2010-09-30 | $232.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $173.35M derived: sum of 2 quarters · filed 2011-08-09 | $123.24M 10-Q · filed 2010-10-28 | $10.77M derived: sum of 4 quarters · filed 2011-08-09 |
| 2010-06-30 | -$58.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09 | -$109.05M 10-Q · filed 2011-08-09 | -$221.53M derived: sum of 3 quarters · filed 2011-08-09 | -$71.34M derived: sum of 4 quarters · filed 2011-08-09 |
| 2010-03-31 | -$50.11M 10-Q · filed 2011-05-06 | -$162.59M derived: sum of 2 quarters · filed 2011-05-06 | -$12.40M derived: sum of 3 quarters · filed 2011-05-06 | -$205.65M derived: sum of 4 quarters · filed 2011-05-06 |
| 2009-12-31 | -$112.47M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-17 | $37.71M derived: sum of 2 quarters · filed 2011-02-17 | -$155.54M derived: sum of 3 quarters · filed 2011-02-17 | $57.54M 10-K · filed 2011-02-17 |
| 2009-09-30 | $150.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | -$43.07M derived: sum of 2 quarters · filed 2010-10-28 | $170.02M 10-Q · filed 2010-10-28 | |
| 2009-06-30 | -$193.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-03 | $19.83M 10-Q · filed 2010-08-03 | ||
| 2009-03-31 | $213.08M 10-Q · filed 2010-05-03 | |||
| 2008-12-31 | $33.45M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |